Your doctor will also likely delve into the nitty-gritty on those symptoms to get a better sense of the issue. As Dr. Moldwin ...

Ferring Pharmaceuticals announced today the U.S. Food and Drug Administration (FDA) approved a state-of-the-art drug product manufacturing hub in Parsippany, NJ, for its intravesical non-replicating ...

Ferring expands production of ADSTILADRIN with new Parsippany, NJ, facility, adding to existing manufacturing sites in Kuopio, Finland Capacity expansion and diversification of manufacturing ...

ImmunityBio, Inc. faces stock decline amid fundraising and market selloff. Click to read more on the long-term potential of ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals announced today the U.S. Food and Drug Administration ... Administer ADSTILADRIN by intravesical instillation only.

By 2022, the United States is predicted to hold 87.9% of the market for postoperative pain in North America. It is anticipated that the adoption of opioid treatment will slow the opioid epidemic’s ...

Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025CORAL GABLES, Fla., April 27, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the ...

UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced new data from the OPTIMA II Phase ...

An investigator reported updated findings from the phase 2/3 study QUILT 3.032 using a July 15, 2024 data cutoff.